JP Morgan Chase’s MaxCyte MXCT Stock Holding History
Bought
Maintained
Sold
Other funds holding MXCT
CFM
VP
VCM
MA
BFM
JP Morgan Chase's MXCT Position: Q1 2026 in Review
JP Morgan Chase increased its MaxCyte (MXCT) stake by 1.7% in Q1 2026, buying an estimated $657 and bringing the position to 41,092 shares worth $27.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6427.
JP Morgan Chase first reported a position in MXCT in Q3 2021 and has held it in 19 quarters since. The position peaked at $1.88M in Q1 2023. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.
- JP Morgan Chase held 41,092 shares of MaxCyte worth $27.8K as of Q1 2026.
- JP Morgan Chase bought 704 MaxCyte shares in Q1 2026, an estimated $657.
- MaxCyte made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6427 holding.
- JP Morgan Chase first reported a position in MaxCyte in Q3 2021 and has held it in 19 quarters since.
- JP Morgan Chase's MaxCyte position peaked at $1.88M in Q1 2023.
- 130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.